Antibody ELISA Kits for Tropical Infectious Disease Market Size to Hit USD 4.41 Billion by 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antibody ELISA Kits For Tropical Infectious Disease Market

5.1. COVID-19 Landscape: Antibody ELISA Kits For Tropical Infectious Disease Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By Disease Type

8.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by Disease Type

8.1.1. Dengue

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Malaria

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Chikungunya

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. Zika Virus

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Yellow Fever

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Lassa Fever

8.1.6.1. Market Revenue and Volume Forecast

8.1.7. Ebola Virus

8.1.7.1. Market Revenue and Volume Forecast

8.1.8. Leptospirosis

8.1.8.1. Market Revenue and Volume Forecast

8.1.9. Schistosomiasis

8.1.9.1. Market Revenue and Volume Forecast

8.1.10. Leishmaniasis

8.1.10.1. Market Revenue and Volume Forecast

8.1.11. Trypanosomiasis

8.1.11.1. Market Revenue and Volume Forecast

8.1.12. Filariasis

8.1.12.1. Market Revenue and Volume Forecast

8.1.13. Others (e.g., Japanese Encephalitis, West Nile Virus, Marburg Virus)

8.1.13.1. Market Revenue and Volume Forecast

Chapter 9. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By Antibody Type

9.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by Antibody Type

9.1.1. IgG

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. IgM

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. IgA

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. IgG/IgM Combo

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Total Antibody

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Others (e.g., IgE, secretory IgA)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By Sample Type

10.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by Sample Type

10.1.1. Serum

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Plasma

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Whole Blood

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Cerebrospinal Fluid (CSF)

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Saliva

10.1.5.1. Market Revenue and Volume Forecast

10.1.6. Others (e.g., urine, dried blood spots)

10.1.6.1. Market Revenue and Volume Forecast

Chapter 11. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By Technology Platform

11.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by Technology Platform

11.1.1. Direct ELISA

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Indirect ELISA

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Sandwich ELISA

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Competitive ELISA

11.1.4.1. Market Revenue and Volume Forecast

11.1.5. Multiplex ELISA

11.1.5.1. Market Revenue and Volume Forecast

11.1.6. Others (e.g., microplate-based ELISA, magnetic bead ELISA)

11.1.6.1. Market Revenue and Volume Forecast

Chapter 12. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By End User

12.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by End User

12.1.1. Hospitals & Clinics

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Diagnostic Laboratories

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Public Health Agencies

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Research Institutes

12.1.4.1. Market Revenue and Volume Forecast

12.1.5. NGOs & International Health Organizations

12.1.5.1. Market Revenue and Volume Forecast

12.1.6. Others (e.g., military health units, mobile diagnostic centers)

12.1.6.1. Market Revenue and Volume Forecast

Chapter 13. Global Antibody ELISA Kits For Tropical Infectious Disease Market, By Distribution Channel

13.1. Antibody ELISA Kits For Tropical Infectious Disease Market Revenue and Volume, by Distribution Channel

13.1.1. Direct Sales

13.1.1.1. Market Revenue and Volume Forecast

13.1.2. Distributors/Wholesalers

13.1.2.1. Market Revenue and Volume Forecast

13.1.3. Online Platforms

13.1.3.1. Market Revenue and Volume Forecast

13.1.4. Tenders/Government Supply Contracts

13.1.4.1. Market Revenue and Volume Forecast

13.1.5. Others (e.g., humanitarian aid programs)

13.1.5.1. Market Revenue and Volume Forecast

Chapter 14. Global Antibody ELISA Kits For Tropical Infectious Disease Market, Regional Estimates and Trend Forecast

14.1. North America

14.1.1. Market Revenue and Volume Forecast, by Disease Type

14.1.2. Market Revenue and Volume Forecast, by Antibody Type

14.1.3. Market Revenue and Volume Forecast, by Sample Type

14.1.4. Market Revenue and Volume Forecast, by Technology Platform

14.1.5. Market Revenue and Volume Forecast, by End User

14.1.6. Market Revenue and Volume Forecast, by Distribution Channel

14.1.7. U.S.

14.1.7.1. Market Revenue and Volume Forecast, by Disease Type

14.1.7.2. Market Revenue and Volume Forecast, by Antibody Type

14.1.7.3. Market Revenue and Volume Forecast, by Sample Type

14.1.7.4. Market Revenue and Volume Forecast, by Technology Platform

14.1.8. Market Revenue and Volume Forecast, by End User

14.1.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.1.9. Rest of North America

14.1.9.1. Market Revenue and Volume Forecast, by Disease Type

14.1.9.2. Market Revenue and Volume Forecast, by Antibody Type

14.1.9.3. Market Revenue and Volume Forecast, by Sample Type

14.1.9.4. Market Revenue and Volume Forecast, by Technology Platform

14.1.10. Market Revenue and Volume Forecast, by End User

14.1.11. Market Revenue and Volume Forecast, by Distribution Channel

14.1.11.1.

14.2. Europe

14.2.1. Market Revenue and Volume Forecast, by Disease Type

14.2.2. Market Revenue and Volume Forecast, by Antibody Type

14.2.3. Market Revenue and Volume Forecast, by Sample Type

14.2.4. Market Revenue and Volume Forecast, by Technology Platform

14.2.5. Market Revenue and Volume Forecast, by End User

14.2.6. Market Revenue and Volume Forecast, by Distribution Channel

14.2.8. UK

14.2.8.1. Market Revenue and Volume Forecast, by Disease Type

14.2.8.2. Market Revenue and Volume Forecast, by Antibody Type

14.2.8.3. Market Revenue and Volume Forecast, by Sample Type

14.2.9. Market Revenue and Volume Forecast, by Technology Platform

14.2.10. Market Revenue and Volume Forecast, by End User

14.2.10.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.11. Germany

14.2.11.1. Market Revenue and Volume Forecast, by Disease Type

14.2.11.2. Market Revenue and Volume Forecast, by Antibody Type

14.2.11.3. Market Revenue and Volume Forecast, by Sample Type

14.2.12. Market Revenue and Volume Forecast, by Technology Platform

14.2.13. Market Revenue and Volume Forecast, by End User

14.2.14. Market Revenue and Volume Forecast, by Distribution Channel

14.2.15. France

14.2.15.1. Market Revenue and Volume Forecast, by Disease Type

14.2.15.2. Market Revenue and Volume Forecast, by Antibody Type

14.2.15.3. Market Revenue and Volume Forecast, by Sample Type

14.2.15.4. Market Revenue and Volume Forecast, by Technology Platform

14.2.16. Market Revenue and Volume Forecast, by End User

14.2.16.1. Market Revenue and Volume Forecast, by Distribution Channel

14.2.17. Rest of Europe

14.2.17.1. Market Revenue and Volume Forecast, by Disease Type

14.2.17.2. Market Revenue and Volume Forecast, by Antibody Type

14.2.17.3. Market Revenue and Volume Forecast, by Sample Type

14.2.17.4. Market Revenue and Volume Forecast, by Technology Platform

14.2.18. Market Revenue and Volume Forecast, by End User

14.2.18.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3. APAC

14.3.1. Market Revenue and Volume Forecast, by Disease Type

14.3.2. Market Revenue and Volume Forecast, by Antibody Type

14.3.3. Market Revenue and Volume Forecast, by Sample Type

14.3.4. Market Revenue and Volume Forecast, by Technology Platform

14.3.5. Market Revenue and Volume Forecast, by End User

14.3.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.7. India

14.3.7.1. Market Revenue and Volume Forecast, by Disease Type

14.3.7.2. Market Revenue and Volume Forecast, by Antibody Type

14.3.7.3. Market Revenue and Volume Forecast, by Sample Type

14.3.7.4. Market Revenue and Volume Forecast, by Technology Platform

14.3.8. Market Revenue and Volume Forecast, by End User

14.3.9. Market Revenue and Volume Forecast, by Distribution Channel

14.3.10. China

14.3.10.1. Market Revenue and Volume Forecast, by Disease Type

14.3.10.2. Market Revenue and Volume Forecast, by Antibody Type

14.3.10.3. Market Revenue and Volume Forecast, by Sample Type

14.3.10.4. Market Revenue and Volume Forecast, by Technology Platform

14.3.11. Market Revenue and Volume Forecast, by End User

14.3.11.1. Market Revenue and Volume Forecast, by Distribution Channel

14.3.12. Japan

14.3.12.1. Market Revenue and Volume Forecast, by Disease Type

14.3.12.2. Market Revenue and Volume Forecast, by Antibody Type

14.3.12.3. Market Revenue and Volume Forecast, by Sample Type

14.3.12.4. Market Revenue and Volume Forecast, by Technology Platform

14.3.12.5. Market Revenue and Volume Forecast, by End User

14.3.12.6. Market Revenue and Volume Forecast, by Distribution Channel

14.3.13. Rest of APAC

14.3.13.1. Market Revenue and Volume Forecast, by Disease Type

14.3.13.2. Market Revenue and Volume Forecast, by Antibody Type

14.3.13.3. Market Revenue and Volume Forecast, by Sample Type

14.3.13.4. Market Revenue and Volume Forecast, by Technology Platform

14.3.13.5. Market Revenue and Volume Forecast, by End User

14.3.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4. MEA

14.4.1. Market Revenue and Volume Forecast, by Disease Type

14.4.2. Market Revenue and Volume Forecast, by Antibody Type

14.4.3. Market Revenue and Volume Forecast, by Sample Type

14.4.4. Market Revenue and Volume Forecast, by Technology Platform

14.4.5. Market Revenue and Volume Forecast, by End User

14.4.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.7. GCC

14.4.7.1. Market Revenue and Volume Forecast, by Disease Type

14.4.7.2. Market Revenue and Volume Forecast, by Antibody Type

14.4.7.3. Market Revenue and Volume Forecast, by Sample Type

14.4.7.4. Market Revenue and Volume Forecast, by Technology Platform

14.4.8. Market Revenue and Volume Forecast, by End User

14.4.9. Market Revenue and Volume Forecast, by Distribution Channel

14.4.10. North Africa

14.4.10.1. Market Revenue and Volume Forecast, by Disease Type

14.4.10.2. Market Revenue and Volume Forecast, by Antibody Type

14.4.10.3. Market Revenue and Volume Forecast, by Sample Type

14.4.10.4. Market Revenue and Volume Forecast, by Technology Platform

14.4.11. Market Revenue and Volume Forecast, by End User

14.4.12. Market Revenue and Volume Forecast, by Distribution Channel

14.4.13. South Africa

14.4.13.1. Market Revenue and Volume Forecast, by Disease Type

14.4.13.2. Market Revenue and Volume Forecast, by Antibody Type

14.4.13.3. Market Revenue and Volume Forecast, by Sample Type

14.4.13.4. Market Revenue and Volume Forecast, by Technology Platform

14.4.13.5. Market Revenue and Volume Forecast, by End User

14.4.13.6. Market Revenue and Volume Forecast, by Distribution Channel

14.4.14. Rest of MEA

14.4.14.1. Market Revenue and Volume Forecast, by Disease Type

14.4.14.2. Market Revenue and Volume Forecast, by Antibody Type

14.4.14.3. Market Revenue and Volume Forecast, by Sample Type

14.4.14.4. Market Revenue and Volume Forecast, by Technology Platform

14.4.14.5. Market Revenue and Volume Forecast, by End User

14.4.14.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5. Latin America

14.5.1. Market Revenue and Volume Forecast, by Disease Type

14.5.2. Market Revenue and Volume Forecast, by Antibody Type

14.5.3. Market Revenue and Volume Forecast, by Sample Type

14.5.4. Market Revenue and Volume Forecast, by Technology Platform

14.5.5. Market Revenue and Volume Forecast, by End User

14.5.6. Market Revenue and Volume Forecast, by Distribution Channel

14.5.7. Brazil

14.5.7.1. Market Revenue and Volume Forecast, by Disease Type

14.5.7.2. Market Revenue and Volume Forecast, by Antibody Type

14.5.7.3. Market Revenue and Volume Forecast, by Sample Type

14.5.7.4. Market Revenue and Volume Forecast, by Technology Platform

14.5.8. Market Revenue and Volume Forecast, by End User

14.5.8.1. Market Revenue and Volume Forecast, by Distribution Channel

14.5.9. Rest of LATAM

14.5.9.1. Market Revenue and Volume Forecast, by Disease Type

14.5.9.2. Market Revenue and Volume Forecast, by Antibody Type

14.5.9.3. Market Revenue and Volume Forecast, by Sample Type

14.5.9.4. Market Revenue and Volume Forecast, by Technology Platform

14.5.9.5. Market Revenue and Volume Forecast, by End User

14.5.9.6. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 15. Company Profiles

15.1. Abbott Laboratories

15.1.1. Company Overview

15.1.2. Product Offerings

15.1.3. Financial Performance

15.1.4. Recent Initiatives

15.2. Bio-Rad Laboratories

15.2.1. Company Overview

15.2.2. Product Offerings

15.2.3. Financial Performance

15.2.4. Recent Initiatives

15.3. Thermo Fisher Scientific

15.3.1. Company Overview

15.3.2. Product Offerings

15.3.3. Financial Performance

15.3.4. Recent Initiatives

15.4. Euroimmun (a PerkinElmer Company)

15.4.1. Company Overview

15.4.2. Product Offerings

15.4.3. Financial Performance

15.4.4. Recent Initiatives

15.5. InBios International

15.5.1. Company Overview

15.5.2. Product Offerings

15.5.3. Financial Performance

15.5.4. Recent Initiatives

15.6. SD Biosensor

15.6.1. Company Overview

15.6.2. Product Offerings

15.6.3. Financial Performance

15.6.4. Recent Initiatives

15.7. Bio-Techne Corporation

15.7.1. Company Overview

15.7.2. Product Offerings

15.7.3. Financial Performance

15.7.4. Recent Initiatives

15.8. Omega Diagnostics

15.8.1. Company Overview

15.8.2. Product Offerings

15.8.3. Financial Performance

15.8.4. Recent Initiatives

15.9. Creative Diagnostics

15.9.1. Company Overview

15.9.2. Product Offerings

15.9.3. Financial Performance

15.9.4. Recent Initiatives

15.10. DRG International

15.10.1. Company Overview

15.10.2. Product Offerings

15.10.3. Financial Performance

15.10.4. Recent Initiatives

Chapter 16. Research Methodology

16.1. Primary Research

16.2. Secondary Research

16.3. Assumptions

Chapter 17. Appendix

17.1. About Us

17.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The antibody ELISA kits for tropical infectious disease market size is expected to increase from USD 2.39 billion in 2024 to USD 4.41 billion by 2034.

The antibody ELISA kits for tropical infectious disease market is expected to grow at a compound annual growth rate (CAGR) of around 6.32% from 2025 to 2034.

The major players in the antibody ELISA kits for tropical infectious disease market include Abbott Laboratories, Bio-Rad Laboratories, Thermo Fisher Scientific, Euroimmun (a PerkinElmer Company), InBios International, SD Biosensor, Bio-Techne Corporation, Omega Diagnostics, Creative Diagnostics, DRG International, DiaPro Diagnostic Bioprobes, NovaTec Immundiagnostica GmbH, BioServUK, Artron Laboratories, Meridian Bioscience, GenWay Biotech, MyBioSource Inc., Calbiotech Inc., Diagnostic Automation/Cortez Diagnostics Inc., and MP Biomedicals.

The driving factors of the antibody ELISA kits for tropical infectious disease Market are the increasing momentum, driven by public health investment at the global level, increased surveillance programs, and access to diagnostic tests thanks to more widely available and emerging technologies.

Asia Pacific region will lead the global antibody ELISA kits for tropical infectious disease market during the forecast period 2025 to 2034.